Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Hurthle Cell Carcinoma Follow-up

  • Author: Serhat Aytug, MD; Chief Editor: Jules E Harris, MD, FACP, FRCPC  more...
 
Updated: Jun 08, 2016
 

Further Outpatient Care

Outpatient care includes the following:

  • Monitor for signs of hypothyroidism after surgical treatment
  • Levothyroxine therapy should usually be started after the treatment dose of 131I is administered
  • Monitor the patient for signs of hypocalcemia and measure calcium levels
  • Before scanning, instruct the patient to avoid iodine-containing medications and iodine-rich foods; measure urinary iodine in doubtful cases
  • In women of childbearing age, pregnancy must be ruled out
  • Patients should be instructed carefully about radiation precautions prior to 131I treatment and should follow the instructions meticulously when sent home

Thyroxine treatment

The adequacy of therapy is monitored by measuring serum thyroid-stimulating hormone (TSH) approximately 8-12 weeks after treatment begins, with the initial goal being a serum TSH concentration of 0.1 µU/mL or less and a serum T3 concentration within the reference range.

In patients who are at low risk and considered cured, the dose of levothyroxine (T4) is decreased to maintain a low, but detectable, serum TSH concentration (0.1-0.5 µU/mL). In higher-risk patients, higher doses are continued, targeting a serum TSH concentration of 0.1 µU/mL or less.

Clinical and ultrasonographic examinations

Thyroid bed and lymph node areas should be examined routinely. Ultrasonography is recommended in patients at high risk for recurrent disease and in any patient with suspicious clinical findings. Palpable lymph nodes that are small, thin, or reduced in size after an interval of 3 months can be considered benign.

Thyroglobulin measurement

In the follow-up care of patients, thyroglobulin is used as a marker of residual disease, of disease recurrence, and as a prognostic factor. Thyroglobulin is produced only by normal or neoplastic thyroid follicular cells and should be undetectable in patients who have been treated with surgery and radioablation. Thyroglobulin concentrations as low as 1 ng/mL or even lower can be detected with current assays.

Antithyroglobulin antibodies, which are found in approximately 15% of patients with thyroid carcinoma, can produce artifactual alteration in thyroglobulin assay results. These antibodies should always be checked when serum thyroglobulin is measured.

Serum thyroglobulin concentrations were undetectable in a group of patients receiving T4 treatment who have isolated lymph node metastases; therefore, undetectable values do not rule out metastatic lymph node disease. If the patient is thought to have metastases, a lymph node biopsy may be performed.

Chest x-ray

Most patients with abnormal chest x-ray findings have detectable serum thyroglobulin concentrations; therefore, this study might not have an additional value in diagnosing metastatic disease. However, it still can have a limited diagnostic value in a subgroup of patients.

Iodine-131 total body scanning

If the serum thyroglobulin concentration becomes detectable in patients receiving T4, recombinant human thyrotropin (thyrotropin alfa; Thyrogen) should be administered or the T4 should be withdrawn, an131 I total-body scan should be obtained, and serum thyroglobulin should be measured. The uptake of 131I and the level of TSH concentration determine the accuracy of total body scanning. In patients whose T4 is withheld, the serum TSH concentration usually should be higher than 30 µU/mL when the total-body scan is performed.

Intramuscular injection of thyrotropin alfa is a promising alternative because T4 treatment does not need to be discontinued and the adverse effects are minimal. Thyroglobulin measurement and total body scanning after thyrotropin alfa administration is currently the standard of care in many institutions. For routine diagnostic scans, 2-5 mCi (74-185 mBq [millibecquerel]) of 131I is administered; higher doses may reduce the uptake of a subsequent therapeutic dose of 131I.

Scanning is performed to measure uptake, if any, 3 days after the thyrotropin alfa dose has been administered. In certain situations, uptake cannot be detected with diagnostic scans when 2-5 mCi of 131I is administered but may be detectable after the administration of 100 mCi. This is the rationale for administering 100 mCi (or more) of 131I in patients with elevated serum thyroglobulin concentrations (usually levels >10 ng/mL after T4 has been withdrawn). If this approach is taken, total-body scanning should be performed 4-7 days later.

If any uptake is detected on the 131I total-body scan or the serum thyroglobulin concentration rises above the previous level, 131I therapy should be administered or a positron emission tomography (PET) scan should be considered to localize the metastasis/recurrence.

In the absence of 131I uptake, a CT scan of the neck and lungs, bone scintigraphy, and scintigraphy using a less-specific tracer (eg, thallium, tetrofosmin, fluorodeoxyglucose) and particularly PET scan should be considered strongly in patients with Hürthle cell carcinoma who are known to have no or low uptake.

Next

Further Inpatient Care

Standard postsurgical care is usually adequate. Monitor patients for signs of infection or hematoma formation.

Clinically monitor patients for hypocalcemic signs and check calcium levels at least every 12-24 hours. If hypocalcemia is present, immediately treat the patient.

Monitor patient for signs of laryngeal nerve injury (eg, hoarseness, respiratory compromise).

If the patient is hospitalized for 131I treatment, administer antiemetics and adequate hydration. Follow effective radiation precautions.

Salivary dysfunction secondary to uptake in salivary glands can be managed with adequate hydration and sucking on candies.

Previous
Next

Deterrence/Prevention

No specific prevention is available, although avoidance of radioactive exposure and adequate iodide intake can be considered preventive measures.

Previous
Next

Complications

Surgical complications include laryngeal nerve injury and transient or permanent hypoparathyroidism. Other surgical complications are infection and hematoma. Surgical scars in the neck can be cosmetically disturbing in certain individuals.

Nonsurgical complications

Hypothyroidism can occur if replacement therapy is inadequate. Hyperthyroidism can occur if the patient is overtreated with levothyroxine.

Acute adverse effects include the following:

  • Nausea or vomiting sialadenitis
  • Radiation-induced effects
  • Thyroiditis
  • In metastatic cases, radiation-induced fibrosis of the lung when large doses of 131 I (>150 mCi) are administered at short intervals
  • Mild pancytopenia observed after repeated 131 I therapy, particularly in patients with bone metastases who also have received external radiotherapy

Genetic defects and infertility may include the following:

  • Transient reduction in spermatogenesis
  • Transient ovarian failure
  • Increased frequency of miscarriages

The risk of secondary carcinoma or leukemia increased only in patients who have received a high cumulative dose of131 I (>500 mCi) and those who also receive external radiation therapy

Previous
Next

Prognosis

Hürthle cell carcinomas behave in a more aggressive fashion than other well-differentiated thyroid cancers, as evidenced by a higher incidence of metastasis and a lower survival rate. Hürthle cell carcinomas produce thyroglobulin. In addition, most Hürthle cell carcinomas have decreased avidity for131 I; therefore, treatment with radioactive iodide has limited efficacy.

In some series, nuclear aneuploidy is present in as many as 90% of patients with Hürthle cell carcinoma; in some studies, this condition is shown to be associated with an adverse prognosis.

In a retrospective review of all patients treated with Hürthle cell carcinoma at their institution between 1946 and 2003 (62 patients in all), Mills et al found that independent predictors of disease-free survival were lymph node status (P = 0.008), presence of metastases at diagnosis (P = 0.005), and tumor stage (P = 0.009). These authors suggest that radical surgery may improve outcome; on multivariate analysis, extent of surgery (P < 0.001) was the only independent factor that affected cause-specific survival.[33]

In a large retrospective study that analyzed the Surveillance, Epidemiology, and End Results (SEER) database from 1988-2009, 3311 patients with Hürthle cell cancer were identified and compared with 59,585 patients with other types of differentiated thyroid cancer. Overall disease-specific survival rates were lower for patients with Hürthle cell cancer (P < 0.001), indicating that Hürthle cell cancer has more aggressive behavior and compromises survival more than other types of differentiated thyroid cancer.[34]

Previous
Next

Patient Education

The need for life-long levothyroxine treatment should be explained to all patients. Radiation precautions should be explained clearly and in detail to patients who will be receiving radioactive iodine treatment. Women of childbearing age should be advised not to become pregnant for at least 1 year after treatment with131 I .

For patient education information, see the Thyroid and Metabolism Center, as well as Thyroid Problems.

Previous
 
Contributor Information and Disclosures
Author

Serhat Aytug, MD Endocrinologist, Division of Endocrinology, Diabetes and Metabolism, St Jude Heritage Medical Group

Serhat Aytug, MD is a member of the following medical societies: American Association of Clinical Endocrinologists, Endocrine Society

Disclosure: Nothing to disclose.

Coauthor(s)

Lawrence E Shapiro, MD Chief, Division of Endocrinology and Metabolism, Professor of Medicine, Department of Medicine, Winthrop University Hospital

Lawrence E Shapiro, MD is a member of the following medical societies: American Diabetes Association, American Thyroid Association, Endocrine Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Jules E Harris, MD, FACP, FRCPC Clinical Professor of Medicine, Section of Hematology/Oncology, University of Arizona College of Medicine, Arizona Cancer Center

Jules E Harris, MD, FACP, FRCPC is a member of the following medical societies: American Association for the Advancement of Science, American Society of Hematology, Central Society for Clinical and Translational Research, American Society of Clinical Oncology

Disclosure: Nothing to disclose.

Additional Contributors

Antoni Ribas, MD Assistant Professor of Medicine, Division of Hematology-Oncology, University of California at Los Angeles Medical Center

Disclosure: Nothing to disclose.

References
  1. Asa SL. My approach to oncocytic tumours of the thyroid. J Clin Pathol. 2004 Mar. 57(3):225-32. [Medline].

  2. Cannon J. The significance of hurthle cells in thyroid disease. Oncologist. 2011. 16 (10):1380-7. [Medline]. [Full Text].

  3. Bronner MP, Clevenger CV, Edmonds PR, Lowell DM, McFarland MM, LiVolsi VA. Flow cytometric analysis of DNA content in Hürthle cell adenomas and carcinomas of the thyroid. Am J Clin Pathol. 1988 Jun. 89(6):764-9. [Medline].

  4. Pisanu A, Sias L, Uccheddu A. Factors predicting malignancy of Hürthle cell tumors of the thyroid: influence on surgical treatment. World J Surg. 2004 Aug. 28(8):761-5. [Medline].

  5. Stojadinovic A, Ghossein RA, Hoos A, Urist MJ, Spiro RH, Shah JP. Hürthle cell carcinoma: a critical histopathologic appraisal. J Clin Oncol. 2001 May 15. 19(10):2616-25. [Medline].

  6. Strazisar B, Petric R, Sesek M, Zgajnar J, Hocevar M, Besic N. Predictive factors of carcinoma in 279 patients with Hürthle cell neoplasm of the thyroid gland. J Surg Oncol. 2010 Jun 1. 101(7):582-6. [Medline].

  7. Guerrero MA, Suh I, Vriens MR, Shen WT, Gosnell J, Kebebew E, et al. Age and tumor size predicts lymph node involvement in Hürthle Cell Carcinoma. J Cancer. 2010 Jun 2. 1:23-6. [Medline]. [Full Text].

  8. Maxwell EL, Palme CE, Freeman J. Hürthle cell tumors: applying molecular markers to define a new management algorithm. Arch Otolaryngol Head Neck Surg. 2006 Jan. 132(1):54-8. [Medline].

  9. Máximo V, Sobrinho-Simões M. Hürthle cell tumours of the thyroid. A review with emphasis on mitochondrial abnormalities with clinical relevance. Virchows Arch. 2000 Aug. 437(2):107-15. [Medline].

  10. Troncone G, Iaccarino A, Russo M, Palmieri EA, Volante M, Papotti M, et al. Accumulation of p27(kip1) is associated with cyclin D3 overexpression in the oxyphilic (Hurthle cell) variant of follicular thyroid carcinoma. J Clin Pathol. 2007 Apr. 60(4):377-81. [Medline].

  11. Troncone G, Iaccarino A, Russo M, Palmieri EA, Volante M, Papotti M, et al. Accumulation of p27(kip1) is associated with cyclin D3 overexpression in the oxyphilic (Hurthle cell) variant of follicular thyroid carcinoma. J Clin Pathol. 2007 Apr. 60(4):377-81. [Medline].

  12. Ganly I, Ricarte Filho J, Eng S, et al. Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy. J Clin Endocrinol Metab. 2013 May. 98(5):E962-72. [Medline].

  13. American Cancer Society. Cancer Facts & Figures 2016. American Cancer Society. Available at http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf. Accessed: June 3, 2016.

  14. Ghossein RA, Hiltzik DH, Carlson DL, Patel S, Shaha A, Shah JP, et al. Prognostic factors of recurrence in encapsulated Hurthle cell carcinoma of the thyroid gland: a clinicopathologic study of 50 cases. Cancer. 2006 Apr 15. 106(8):1669-76. [Medline].

  15. Cooper DS, Schneyer CR. Follicular and Hürthle cell carcinoma of the thyroid. Endocrinol Metab Clin North Am. 1990 Sep. 19(3):577-91. [Medline].

  16. Kushchayeva Y, Duh QY, Kebebew E, Clark OH. Prognostic indications for Hürthle cell cancer. World J Surg. 2004 Dec. 28(12):1266-70. [Medline].

  17. Besic N, Schwarzbartl-Pevec A, Vidergar-Kralj B, Crnic T, Gazic B, Marolt Music M. Treatment and outcome of 32 patients with distant metastases of Hürthle cell thyroid carcinoma: a single-institution experience. BMC Cancer. 2016 Feb 26. 16 (1):162. [Medline].

  18. Máximo V, Botelho T, Capela J, Soares P, Lima J, Taveira A, et al. Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid. Br J Cancer. 2005 May 23. 92(10):1892-8. [Medline].

  19. Pryma DA, Schoder H, Gonen M, Robbins RJ, Larson SM, Yeung HW, et al. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hurthle cell thyroid cancer patients. J Nucl Med. 2006 Aug. 47(8):1260-6. [Medline].

  20. Elliott DD, Pitman MB, Bloom L, Faquin WC. Fine-needle aspiration biopsy of Hurthle cell lesions of the thyroid gland: A cytomorphologic study of 139 cases with statistical analysis. Cancer. 2006 Apr 25. 108(2):102-9. [Medline].

  21. Jacques C, Guillotin D, Fontaine JF, et al. DNA microarray and miRNA analyses reinforce the classification of follicular thyroid tumors. J Clin Endocrinol Metab. 2013 May. 98(5):E981-9. [Medline].

  22. Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012 Aug 23. 367(8):705-15. [Medline].

  23. Donatini G, Beaulieu A, Castagnet M, Kraimps JL, Levillain P, Fromont G. Thyroid Hürthle cell tumors: research of potential markers of malignancy. J Endocrinol Invest. 2016 Feb. 39 (2):153-8. [Medline].

  24. Volante M, Bozzalla-Cassione F, DePompa R, Saggiorato E, Bartolazzi A, Orlandi F, et al. Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid. Virchows Arch. 2004 Aug. 445(2):183-8. [Medline].

  25. Jillard C, Youngwirth L, Scheri R, Roman S, Sosa JA. Radioactive Iodine Treatment is Associated with Improved Survival for Patients with Hürthle Cell Carcinoma. Thyroid. 2016 May 5. [Medline].

  26. Fernández CA, Puig-Domingo M, Lomeña F, Estorch M, Camacho Martí V, Bittini AL, et al. Effectiveness of retinoic acid treatment for redifferentiation of thyroid cancer in relation to recovery of radioiodine uptake. J Endocrinol Invest. 2009 Mar. 32(3):228-33. [Medline].

  27. Kim WG, Kim EY, Kim TY, Ryu JS, Hong SJ, Kim WB, et al. Redifferentiation therapy with 13-cis retinoic acids in radioiodine-resistant thyroid cancer. Endocr J. 2009 Mar. 56(1):105-12. [Medline].

  28. Foote RL, Brown PD, Garces YI, McIver B, Kasperbauer JL. Is there a role for radiation therapy in the management of Hürthle cell carcinoma?. Int J Radiat Oncol Biol Phys. 2003 Jul 15. 56(4):1067-72. [Medline].

  29. Haugen BR, Sherman SI. Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr Rev. 2013 Jun. 34(3):439-55. [Medline]. [Full Text].

  30. Younes MN, Yigitbasi OG, Park YW, Kim SJ, Jasser SA, Hawthorne VS, et al. Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation. Cancer Res. 2005 Jun 1. 65(11):4716-27. [Medline].

  31. Younes MN, Yazici YD, Kim S, Jasser SA, El-Naggar AK, Myers JN. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer. Clin Cancer Res. 2006 Jun 1. 12(11 Pt 1):3425-34. [Medline].

  32. Paphavasit A, Thompson GB, Hay ID, Grant CS, van Heerden JA, Ilstrup DM, et al. Follicular and Hürthle cell thyroid neoplasms. Is frozen-section evaluation worthwhile?. Arch Surg. 1997 Jun. 132(6):674-8; discussion 678-80. [Medline].

  33. Mills SC, Haq M, Smellie WJ, Harmer C. Hürthle cell carcinoma of the thyroid: Retrospective review of 62 patients treated at the Royal Marsden Hospital between 1946 and 2003. Eur J Surg Oncol. 2009 Mar. 35(3):230-4. [Medline].

  34. Goffredo P, Roman SA, Sosa JA. Hurthle cell carcinoma: a population-level analysis of 3311 patients. Cancer. 2013 Feb 1. 119(3):504-11. [Medline].

  35. Arganini M, Behar R, Wu TC, Straus F 2nd, McCormick M, DeGroot LJ, et al. Hürthle cell tumors: a twenty-five-year experience. Surgery. 1986 Dec. 100(6):1108-15. [Medline].

  36. Azadian A, Rosen IB, Walfish PG, Asa SL. Management considerations in Hürthle cell carcinoma. Surgery. 1995 Oct. 118(4):711-4; discussion 714-5. [Medline].

  37. Chen H, Nicol TL, Zeiger MA, Dooley WC, Ladenson PW, Cooper DS, et al. Hürthle cell neoplasms of the thyroid: are there factors predictive of malignancy?. Ann Surg. 1998 Apr. 227(4):542-6. [Medline].

  38. Cheung CC, Ezzat S, Ramyar L, Freeman JL, Asa SL. Molecular basis off hurthle cell papillary thyroid carcinoma. J Clin Endocrinol Metab. 2000 Feb. 85(2):878-82. [Medline].

  39. Devita VT, Hellman S, Rosenberg SA. Cancer of the Endocrine System. Cancer: Principles and Practice of Oncology. 7th Ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2004.

  40. Fagin JA. Molecular genetics of tumors of thyroid follicular cells. Werner & Ingbar's The Thyroid. Philadelphia, Pa: Lippincott, Williams, & Wilkins; 2000. 886-94.

  41. Gosain AK, Clark OH. Hürthle cell neoplasms. Malignant potential. Arch Surg. 1984 May. 119(5):515-9. [Medline].

  42. Grant CS. Operative and postoperative management of the patient with follicular and Hürthle cell carcinoma. Do they differ?. Surg Clin North Am. 1995 Jun. 75(3):395-403. [Medline].

  43. Grünwald F, Menzel C, Bender H, Palmedo H, Otte R, Fimmers R, et al. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med. 1998 Nov. 39(11):1903-6. [Medline].

  44. Larsen PR, Davies TF, Hay IA. Molecular Pathogenesis (Follicular carcinoma). Williams Textbook of Endocrinology. Philadelphia, Pa: WB Saunders, Co; 1998. 490-3.

  45. Luna-Ortiz K, Hurtado-Lopez LM, Valderrama-Landaeta JL, Ruiz-Vega A. Thyroglossal duct cyst with papillary carcinoma: what must be done?. Thyroid. 2004 May. 14(5):363-6. [Medline].

  46. Mazzaferri EL. Thyroid cancer in thyroglossal duct remnants: a diagnostic and therapeutic dilemma. Thyroid. 2004 May. 14(5):335-6. [Medline].

  47. McDonald MP, Sanders LE, Silverman ML, Chan HS, Buyske J. Hürthle cell carcinoma of the thyroid gland: prognostic factors and results of surgical treatment. Surgery. 1996 Dec. 120(6):1000-4; discussion 1004-5. [Medline].

  48. McHenry CR, Sandoval BA. Management of follicular and Hurthle cell neoplasms of the thyroid gland. Surg Oncol Clin N Am. 1998 Oct. 7(4):893-910. [Medline].

  49. Papotti M, Torchio B, Grassi L, Favero A, Bussolati G. Poorly differentiated oxyphilic (Hurthle cell) carcinomas of the thyroid. Am J Surg Pathol. 1996 Jun. 20(6):686-94. [Medline].

  50. Ron E, Schneider AB. Thyroid Cancer. Schottenfeld, D Fraumeni J eds. Cancer. Epidemiology and Prevention. 3rd ed. Oxford University Press: 2006.

  51. Rosen IB, Luk S, Katz I. Hürthle cell tumor behavior: dilemma and resolution. Surgery. 1985 Oct. 98(4):777-83. [Medline].

  52. Sanders LE, Silverman M. Follicular and Hurthle cell carcinoma: predicting outcome and directing therapy. Surgery. 1998 Dec. 124(6):967-74. [Medline].

  53. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998 Jan 29. 338(5):297-306. [Medline].

  54. Tallini G. Oncocytic tumours. Virchows Arch. 1998 Jul. 433(1):5-12. [Medline].

  55. Watson RG, Brennan MD, Goellner JR, van Heerden JA, McConahey WM, Taylor WF. Invasive Hürthle cell carcinoma of the thyroid: natural history and management. Mayo Clin Proc. 1984 Dec. 59(12):851-5. [Medline].

 
Previous
Next
 
Tumor, lymph node, metastases (TNM) staging system for papillary and follicular thyroid carcinoma.
A monomorphous cell population of Hürthle cells arranged in loosely cohesive clusters and single cells. The cells are polyhedral and have abundant granular cytoplasm with well-defined cell borders. The nuclei are enlarged and have a central prominent macronucleolus.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.